§ Vernon CoakerTo ask the Secretary of State for Health, pursuant to his answer of 17 October 2001,Official Report, column 1240W, on beta interferon (No. 7427), what assessment he has made of the cost of beta interferon (a) in the UK and (b) in other countries; and if he will make a statement. [9795]
§ Ms BlearsThe National Institute for Clinical Excellence (NICE) Appraisal Committee further considered the evidence on the use of beta interferon and glatiramer acetate for multiple sclerosis sufferers on 25 September 2001. NICE has subsequently issued a provisional appraisal determination (PAD) to interested parties for comment.
The institute has stated that, to allow sufficient time to take proper account of the extensive comments received on the PAD, it issued the final appraisal determination to consultees on 30 October.
Of those on in-patient waiting list, percentage who have waited: Quarter Size of in-patient waiting list More than 6 months More than 9 months More than 12 months More than 18 months More than 24 months March 1981 628,333 n/a n/a 28.8 n/a n/a June 1981 n/a n/a n/a n/a n/a n/a September 1981 619,393 n/a n/a 29.2 n/a n/a December 1981 n/a n/a n/a n/a n/a n/a March 1982 622,480 n/a n/a 28.2 n/a n/a June 1982 n/a n/a n/a n/a n/a n/a September 1982 725,865 n/a n/a 26.6 n/a n/a December 1982 n/a n/a n/a n/a n/a n/a March 1983 726,186 n/a n/a 27.3 n/a n/a June 1983 n/a n/a n/a n/a n/a n/a September 1983 703,755 n/a n/a 29.3 n/a n/a December 1983 n/a n/a n/a n/a n/a n/a March 1984 692,945 n/a n/a 28.1 n/a n/a June 1984 n/a n/a n/a n/a n/a n/a September 1984 682,599 n/a n/a 27.8 n/a n/a December 1984 n/a n/a n/a n/a n/a n/a